Plain-English translation of NCT04687176 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This trial is testing a combination of three medications taken by mouth—arsenic trioxide, all-trans-retinoic acid, and ascorbic acid—for people newly diagnosed with acute promyelocytic leukemia (APL), a rare and serious blood cancer. The goal is to see whether this combination can help put the cancer into remission and keep it under control over time. Some younger patients with higher white blood cell counts may also receive additional chemotherapy drugs.
Acute promyelocytic leukemia is a life-threatening cancer that needs urgent treatment. Researchers want to test whether this medication combination can work well as a first-line treatment, potentially avoiding or reducing the need for traditional chemotherapy in some patients, which could mean fewer side effects and better quality of life.
You likely qualify if…
You likely don't qualify if…
You would take three oral medications daily for 42 days during the initial treatment phase, with blood tests and a bone marrow sample taken around day 28 to check how well the treatment is working. After that, you'd continue with two shorter cycles of the same medications (14 days every 4 weeks), followed by a year-long maintenance phase with the treatment given for 2 weeks every 8 weeks. Throughout the study, you'll have regular blood tests to monitor your disease and treatment response, with follow-up visits continuing for 2 years total.
AI-generated summary from trial data · Jun 18, 2026 · Not medical advice
Hong Kong
Singapore